Neoplasm, Residual

16 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms

Treatments and conditions

Neoplasm, Residual
Treatment and conditionWhere it standsTrials
Blinatumomab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
BLINATUMOMAB + Venetoclax for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Folfoxiri for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
INCA33890 for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-Dose Radiation Therapy (LDRT) for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
mFOLFOXIRI for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Osimertinib for neoplasm, residualTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sugemalimab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tisagenlecleucel for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tki + blinatumomab for neoplasm, residualPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zymosan + α-lactalbumin vaccine for neoplasm, residualPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.